Cosmo Targets Double-Digit Growth, Specialty Mix to Reach 70%

Cosmo First Limited — Q4 & FY26 Earnings Call (held May 21, 2026; results for quarter/year ended Mar 2026)

1. Overall Tone of Management: Optimistic

• Management highlights strong growth and profitability improvement: “EBITDA increase by 53% in Q4” and “26% increase in revenue” for FY26.
• Forward-looking language is confident on demand/utilization and business scaling (e.g., “expects double-digit topline growth next year”, “clear roadmap to reduce net debt”).
• However, they repeatedly hedge on commodity margin predictability (“very difficult… to give any guidance”), which tempers the optimism.

2. Key Themes from Management Commentary

• Volume-led growth post-capex commissioning
• Q4 sales up 37% YoY driven by 41% higher volume; FY26 revenue up 26% driven by 27% volume increase.
• Speciality mix as the margin stabilizer
• Specialty films are positioned as “60% of our films” and growing at “about 10% CAGR,” used to “insulates blended margins.”
• Commodity film margins remain volatile, but company is “lowest cost producer”
• BOPP/BOPET margins cited as improving vs Dec-25, but management stresses volatility due to new capacity and supply-demand swings.
• New verticals scaling with improving profitability
• Specialty Chemicals: FY26 topline Rs 204 cr, “25%+ EBITDA”; Q4 sales Rs 54 cr with “25%+ EBITDA.”
• Rigid Packaging (Plastech): reached EBITDA breakeven; FY27 focus on profitability via utilization.
• Consumer businesses:
  • Zigly: Q4 topline +54% YoY.
  • Cosmo Consumer: “gaining traction very substantially,” with approvals and scaling in US/Europe underway.
• Financial resilience / deleveraging
• CAPEX cycle largely complete; focus on “sweating strategic CAPEX done in last 3 years (₹1,200 Cr.)”
• Net debt reduced by Rs 75 cr in last 6 months to Rs 1,159 cr; target to reduce further over next 2 years.
• US tariff relief as a profitability catalyst
• “Recently announced reduction in the USA tariff will lead to improved profitability… from next year.”

3. Q&A Analysis

Theme A: Commodity film pricing/margins (BOPP/BOPET) & industry demand-supply

• Core questions
• Outlook for BOPET/BOPP spreads in FY27; current demand-supply and whether spreads will rise.
• Why margins changed (inventory/port effects; lag in specialty pass-through).
• Management response
• Margins “may remain volatile” due to new capacity; they control “mix and cost.”
• BOPP spreads: “ranging broadly in the similar range of Quarter 4.”
• BOPET: supply still “a bit more than demand” and margins fluctuate; “trend says that yes, it should increase.”
• Inventory explanation for margin: finished goods “at the port at the end of the year,” so margin benefit got “parked… in transit.”
• Specialty margin lag: “Speciality… lag of one to three months” vs core films pass-through “almost on an immediate basis.”
• Notable / evasive elements
• They avoid quantitative FY27 margin guidance repeatedly: “difficult… to give any projections” / “cannot comment” on mix-driven outcomes.

Theme B: Specialty films mix trajectory (share of speciality; reaching 70%)

• Core questions
• When will speciality reach 70% (back to FY25 Q4 levels)?
• How specialty share changed after new lines; timeline to recover.
• Management response
• Q4 speciality share ~60%; full-year 56–57%.
• “It will be roughly 18–24 months” to reach 70%.
• Specialty growth expected to remain ~10% CAGR; mix improves gradually as new lines ramp and specialty conversion increases.
• Strong/clear answer
• The 18–24 months timeline is a relatively concrete commitment.

Theme C: Consumer businesses scaling & profitability (Zigly, Cosmo Consumer)

• Core questions
• What value-unlocking plans exist for Zigly in FY27?
• Guidance for profitability timing and incremental spend for Cosmo Consumer and Plastech.
• US/Europe scaling status and approvals.
• Management response
• Zigly value unlock: “separate subsidiary” and exploring “external capital.”
• Cosmo Consumer profitability:
  • Gross margins guided at 35–40%.
  • FY26 losses attributed to brand-building marketing; EBITDA breakeven “without marketing costs.”
  • Profitability path: Plastech high single-digit EBITDA in FY27, high/mid-teens in FY28.
  • Cosmo Consumer: “will take at least couple of years” and “at least… reach INR 100 crores benchmark.”
• US/Europe scaling: dispatching already; scaling takes time due to customer pallet-to-container ramp.
• Evasive/partial
• They do not provide a clear quantitative PBT-positive date for Cosmo Consumer beyond “couple of years” and the INR 100 cr milestone.

Theme D: Debt, ROCE, and capex cycle

• Core questions
• How much debt will reduce in FY27/FY28; interest cost outlook.
• ROCE/ROE expectations post-capex.
• Management response
• Debt reduction target: bring debt “below 2x within 12 to 18 months.”
• ROCE: FY26 impacted; “FY26… 11%,” next year “around 14% to 15%,” expected to rise with utilization and new business growth.
• Interest cost not given explicitly, but they emphasize reduced CAPEX next year (<₹100 cr).
• Credibility note
• They give a directional ROCE range and a timing for leverage improvement, but avoid a precise FY27/FY28 net debt number.

Theme E: US tariff refund mechanics (court process)

• Core questions
• Whether Cosmo US filed for refund; expected quantum and timing.
• Management response
• Refund process: courts opened; “studying… and going to file… soon.”
• Timing: “6 months to 12 months.”
• Quantum: “more than INR 60 crores,” with some portion potentially returned to customers; will know exact situation later.
• Strong specificity
• Provides timing and magnitude, though net P&L impact depends on customer pass-through.

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY27 topline growth: “double-digit topline growth next year”
• US business growth (qualitative-to-quantitative): “anywhere between 15 to 20% growth as a minimum in US business”
• Capacity utilization
• Full-year film business utilization: “80% to 85%”
• Additional opportunity: “15% to 20% growth potential” from last year’s numbers
• Specialty mix
• Q4 speciality ~60%; full-year 56–57%
• Time to reach 70%: “roughly 18–24 months”
• Plastech profitability
• FY27: “high single-digit EBITDA”
• FY28: “high or mid-teens EBITDA”
• ROCE
• FY26 ROCE: “11%”
• FY27: “around 14% to 15%”
• Debt
• Target: “below 2x within 12 to 18 months”
• CAPEX next year expected < ₹100 cr (implied from “expected to be less than INR 100 crores”)

Implicit signals (qualitative)

• Margin outlook
• Core film margins will remain volatile; they emphasize specialty growth and cost leadership rather than predicting spreads.
• Demand environment
• Flexible packaging volumes growing 8–10% YoY (used to support volume growth and share gains).
• Competitive landscape
• They expect oversupply risk in core films to be temporary (“could be some oversupply… for a short period”).
• Consumer scaling
• Confidence in trajectory: Cosmo Consumer “gaining traction very substantially,” and they cite exit run-rate milestones (e.g., PPF/PPF-related business annualized run rate and Q4 exit rate for PPF).

5. Standout Statements (most revealing)

• Profitability improvement despite volatility
• “EBITDA increase by 53% in Q4 to Rs. 130 crores”
• Specialty as the core strategy
• “Speciality Films are 60% of our films and are growing… insulates blended margins”
• Deleveraging roadmap
• “clear roadmap to reduce net debt over next 2 years” and “bring it below within next 12 to 18 months”
• US tariff relief + refund
• “Recently announced reduction in the USA tariff will lead to improved profitability… from next year”
• Refund: “refund will be more than INR 60 crores” and “expected… 6 months to 12 months”
• Specialty mix recovery timeline
• “It will be roughly 18-24 months” to reach 70% speciality
• Margin guidance refusal
• “EBITDA… we cannot talk about industry cycles… difficult… to give any guidance” (repeated)

6. Red Flags / Positive Signals

Positive signals
– Strong execution on volume growth and specialty scaling (specialty chemicals EBITDA expansion; films specialty share rising to 60%).
– Clear capital allocation narrative: capex cycle largely complete; focus on utilization and ROCE.
– Concrete timelines for leverage (12–18 months to <2x) and specialty mix (18–24 months to 70%).

Red flags
– Limited quantitative margin guidance despite repeated questions—management leans on “volatility” and “mix/cost control.”
– Consumer profitability path remains milestone-based and time-lagged (“couple of years,” “INR 100 crores benchmark”) without detailed PBT timing.
– Some answers are conditional (e.g., US refund net benefit depends on customer pass-through).

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Current call tone vs Feb 2026 / Nov 2025: More Optimistic
• Feb 2026 emphasized tariff headwinds and margin pressure; Nov 2025 also highlighted import-driven margin declines and US tariff impact.
• In May 2026, management leads with results strength and tariff relief/refund catalysts, plus stronger deleveraging progress.
• Shift drivers
• Narrative moved from “uncertainty/impact quantification” (tariffs, imports, stabilization costs) to “utilization + specialty growth + debt reduction.”
• More willingness to provide specific timelines (specialty to 70%, debt below 2x).

b. Tracking Past Commitments vs Outcomes

• Past statement (Feb 12, 2026): “Capex cycle… largely complete” and “no major capex planned” with net debt reduction roadmap.
• Expected: debt reduction over 2–3 years; utilization ramp.
• Current evidence: net debt reduced by Rs 75 cr in last 6 months to Rs 1,159 cr; capex cycle described as “largely complete.”
• Assessment: ✅ On track (at least directionally delivered; exact end-state not quantified).
• Past statement (Feb 12, 2026): US tariff reduction expected to improve profitability from Q1 FY27 once higher-duty inventory exhausted.
• Current: reiterates improved profitability “from next year” (consistent).
• Assessment: ✅ Consistent.
• Past statement (Nov 12, 2025): BOPP new line ramp to full utilization by Q4 FY26.
• Current: film utilization guided 80–85% and “opportunity to increase volumes by another 15–20%,” implying ramp is progressing but not necessarily “full” across all lines.
• Assessment: ⏳ Partially delivered (utilization strong, but they still describe capacity opportunity rather than “fully at nameplate”).
• Past statement (Nov 12, 2025): Zigly profitability “may easily take three to four years.”
• Current: still “at least couple of years” for Cosmo Consumer; Zigly value unlock via subsidiary/external capital, but no clear profitability date.
• Assessment: ⏳ Not clearly delivered (still time-lagged; no new profitability milestone for Zigly).

c. Narrative Shifts

• Commodity margin focus reduced: earlier calls spent more time quantifying tariff/import impacts and margin levels; now they emphasize specialty share and cost leadership.
• Consumer strategy becomes more structural: Zigly demerger/subsidiary/external capital exploration is more explicit now (vs earlier demerger plan timeline).
• US becomes dual catalyst: not only tariff reduction but also court refund process and expected quantum.

d. Consistency & Credibility Signals

• Credibility: Medium
• Strength: consistent strategic pillars (sweat capex, specialty growth, deleveraging).
• Weakness: repeated refusal to give margin guidance and reliance on “volatility/mix” makes it harder to underwrite near-term earnings quality.
• Debt/ROCE timelines are clearer than margin timelines, improving credibility somewhat.

e. Evolution of Key Themes

• Demand/margins (core films): volatile → “range-bound” for BOPP in Q4; still uncertain for BOPET.
• Specialty mix: steady upward trajectory but still below prior peak; now quantified recovery timeline (18–24 months to 70%).
• Deleveraging: increasingly quantified (net debt reduction amount and leverage target).
• Consumer businesses: from “scaling” to “profitability milestones + brand investment explanation,” but still lacks hard PBT timing.

f. Additional Cross-Period Insights

• Inventory/port timing is now used to explain margin movements (May call), suggesting management is increasingly attributing quarter-to-quarter margin noise to working-capital mechanics rather than underlying pricing power.
• US refund introduces a new potential earnings/cash-flow swing not present in earlier calls—this can improve cash generation but also adds uncertainty around customer pass-through.